10x Genomics Bets Its Future on Atera While 2026 Revenue Growth Remains Muted at 0-4%
Q1 2026 Earnings Call, May 7, 2026 — Company Posts $151M in Revenue, Launches Most Significant Product in Its History
10x Genomics opened 2026 with a solid but unspectacular quarter, posting $150.8 million in revenue, up 9% year-over-year excluding a non-recurring settlement payment in the prior period. The headline number, however, is almost beside the point. The company's entire investment thesis is now orbiting a single product: Atera, a new spatial biology instrument that CEO Serge Saxonov called "the most significant product introduction in our history" — and the early customer response, by all accounts, has been extraordinary. The harder question for investors is what happens to revenue in the intervening quarters while the world waits for Atera to actually ship.
Atera: What It Does and Why It Matters
Atera is not an incremental upgrade. The platform is designed to resolve what Saxonov described as the central frustration of spatial biology to date — that researchers have been forced into painful trade-offs between throughput, specificity, sensitivity, and scale, gaining in one dimension only by sacrificing in another. Atera is built to eliminate those trade-offs simultaneously. It delivers whole transcriptome analysis with single-cell sensitivity, high specificity through refined probe chemistry, and a step-change in throughput: a single instrument can process up to 800 whole transcriptome one-centimeter-squared samples per year, or more than 3,000 using targeted Atera Select panels.
Critically, Atera runs on standard off-the-shelf glass slides, which makes it compatible with archived biobank samples and enables distributed sample collection across sites — a meaningful unlock for large clinical cohort studies that were previously impractical. The platform also performs the most computationally intensive step, image processing, directly on the instrument using onboard GPUs, with data then flowing either to on-premise infrastructure or 10x's cloud platform. The planned roadmap includes workflow automation for sample-in, data-out capability, protein multiomics, and in situ sequencing for spatial mutation detection.
Customer reaction has been striking even by the company's own elevated expectations. "One customer told us that this was the largest technology leap they've seen in their career," Saxonov said. "Another called Atera's capabilities the holy grail." He added, with characteristic understatement, that others used language "that would not be appropriate for me to repeat in this forum."
The Demand Signal Is Real — But Shipments Don't Begin Until H2
Pre-orders are being taken now, with initial shipments expected in the second half of 2026, heavily weighted toward the fourth quarter. CFO Adam Taich put a number on it: approximately 40 units are expected to ship between Q3 and Q4, with the vast majority landing in Q4. Production capacity remains the binding constraint, and 10x is being deliberate about the ramp. The company declined to give specific 2027 production targets, though Saxonov indicated the team is "working as hard as they can to get it done quickly."
Even in what Taich acknowledged remains a "fairly constrained" capital equipment environment, customer conversations are reportedly bypassing the usual budget debates. "Even in a constrained capital environment, customers are finding CapEx," Taich said. "This is the type of launch where folks find money." The company is also timing the launch to align with customer grant submission cycles and 2027 budget planning processes — a deliberate sequencing move to ensure Atera is embedded in forward spending plans.
The Near-Term Revenue Trade-Off Is Significant
The Atera launch creates an unavoidable air pocket in the existing spatial business. Instrument revenue declined 24% in Q1, with spatial instruments down 32% — a weakness Taich attributed primarily to customers pausing Xenium purchases in anticipation of Atera, a dynamic that was visible even before the official announcement given the company's AGBT campaign and NDA-based early access conversations. That dynamic will persist through Q2 and Q3, with the company guiding for a low-single-digit sequential decline in Q2 followed by a broadly similar Q3 before Atera shipments begin to contribute in Q4.
Full-year 2026 guidance is maintained at $600 million to $625 million, implying 0% to 4% growth excluding prior-year settlement revenue. That is not a strong growth profile for a company calling its new product a historic inflection point. Management was transparent about the math: Atera upside in 2026 will be modest given the limited unit count, while pressure on Xenium and Visium will be real. Both dynamics were, they insist, baked into the original guidance. The more consequential setup, Saxonov emphasized repeatedly, is 2027 — when Atera enters its first full year, Flex Apex pricing stabilizes and volume growth converts to revenue growth, and AI-driven research spending scales further.
The AI Tailwind Argument Is Becoming More Concrete
One of the more substantive themes on the call was the company's positioning as infrastructure for biological AI model training. Saxonov was direct: "I don't think at this stage there isn't a large project where AI isn't a big driver or if not the biggest driver of that project." This is not merely positioning — it is showing up in signed partnerships. The company has agreements with the Chan Zuckerberg Initiative on the Billion Cells Project, the Arc Institute, Xaira Therapeutics for the largest perturbation dataset ever reported, and most recently Bioptimus, an AI-focused biotech building STELA, a global initiative targeting 100,000 patient tissue specimens across three continents, starting on Xenium with plans to expand to Atera.
Last week, the Chan Zuckerberg Biohub announced a $500 million Virtual Biology Initiative aimed at building AI models that can simulate cells and tissues in silico — a program that Saxonov framed as analogous in ambition to the Human Genome Project. These are not vague endorsements. They are funded programs that will generate sustained consumable demand. Atera's billion-cell-per-year throughput capacity is directly engineered for this use case, and the company's argument is that scaling laws in biology mirror those in language models: more data, generated at higher quality and across more biological contexts, produces dramatically better models. "As AI models improve, we expect an exponential increase in the demand for the kind of data our technologies produce," Saxonov said.
Single Cell Holding Up; Flex Apex Still Early
On the Single Cell side, consumable revenue grew 6% with double-digit reaction volume growth driven by Flex Apex, which remains the most popular assay by volume. Saxonov was careful to note that Flex Apex is still in early innings — only a partial Q4 launch plus one full quarter of data — and that pricing headwinds from the mix shift are consistent with Q4 trends. The expectation is that as Flex Apex reaches widespread adoption and pricing stabilizes, volume growth will translate more directly into revenue growth. That inflection is now expected to materialize in 2027. Importantly, management dismissed near-term concern about Atera cannibalizing Single Cell volumes, noting the workflow configurations, pricing, and use cases remain sufficiently distinct that no such substitution is visible in customer behavior today.
Financials Show Improving Underlying Health
Gross margin expanded to 70% in Q1 from 68% in the prior year, driven by lower warranty costs and reduced inventory write-downs, partially offsetting the loss of license and royalty revenue. Management guided full-year gross margins to remain in the mid-60s, acknowledging that Atera instruments will carry below-average margins at launch — a typical pattern for new hardware introductions — creating some Q4 pressure. Operating expenses declined 20% year-over-year on an apples-to-apples basis, reflecting lower legal costs as patent litigation activity winds down and reduced headcount costs. The cash position ended the quarter at $540 million, up $113 million year-over-year and $16 million sequentially, a materially improved liquidity profile versus the uncertainty of a year ago when the company withdrew full-year guidance in response to government research funding disruptions.
Visium's Future Grows Murkier
Visium, 10x's sequencing-based spatial platform, faces increasing pressure from both directions — Xenium has already become the preferred spatial imaging platform, and Atera will accelerate that migration further. Saxonov acknowledged the dynamic plainly: "While the launch of Atera is going to put pressure on both Spatial platforms, it's going to put pressure on Visium too." The company intends to continue supporting the platform and cites genuine customer loyalty and ongoing workflows as buffers, but the product trajectory is clearly downward. Visium HD launched just over two years ago, and with Atera now positioned as the spatial standard, future investment prioritization will inevitably tilt away from it.
The 2027 Setup Is the Real Thesis
Saxonov closed the call with an unusually candid articulation of where management's conviction actually lies. "Personally, how excited am I about the setup we have for 2027 and beyond," he said, walking through three convergent tailwinds: Atera's first full year of commercial operation, stabilization of Flex Apex pricing enabling volume to flow through to revenue, and an expected exponential increase in AI-driven research demand alongside scaling translational cohort studies. He added, with an implicit acknowledgment of the company's difficult past year on macro, "at the very least, we will have good compares. And to the extent conditions improve, we should see an acceleration to all the other trends." For investors, the core question is whether they are willing to fund that 2027 narrative through what is likely to be a muted 2026 revenue year, with limited Atera units shipping and the legacy spatial business in a holding pattern.
10x Genomics Deep Dive
Business Model and Core Operations
10x Genomics operates a classic, high-margin razor-and-blade business model that lies at the intersection of hardware engineering, specialized reagent chemistry, and bioinformatics software. The company primarily generates revenue through the sale of highly sophisticated capital equipment and the subsequent, recurring pull-through of specialized proprietary consumables. These tools enable academic and biopharmaceutical researchers to conduct high-resolution profiling of biological systems, specifically through single-cell sequencing and spatial transcriptomics. The hardware lineup historically centers around the Chromium platform for single-cell profiling and the Visium and Xenium platforms for spatial analysis. Once an instrument is placed in a laboratory, it requires a steady stream of 10x Genomics assay kits, microfluidic chips, and specialized slides to operate. These consumables represent the economic engine of the company, commanding gross margins near 70% and accounting for roughly 83% of total revenue. Software is provided alongside the hardware to handle the immense data output, embedding the company deeply into the customer's workflow. This recurring revenue model ensures that as the installed base expands, the top line becomes increasingly predictable, provided that utilization rates remain robust.
Customers, Competitors, and Supply Chain
The customer base of 10x Genomics is highly concentrated within the life sciences research ecosystem, predominantly encompassing academic medical centers, government laboratories, and the research and development arms of top-tier biopharmaceutical companies. These institutions rely on the company to perform complex single-cell and spatial biology assays vital for oncology, immunology, and neurology research. The competitive landscape is fierce and features a mix of established life science behemoths and agile startups. Historically, the company engaged in intense rivalry with NanoString Technologies in the spatial transcriptomics arena. However, after 10x Genomics successfully sued NanoString for patent infringement resulting in a $31 million jury verdict, NanoString was driven into bankruptcy in 2024 and its assets were subsequently acquired by Bruker for $392.6 million. In the single-cell domain, the competitive dynamic has shifted drastically. Massive diagnostic and sequencing conglomerates like Thermo Fisher, Becton Dickinson, and Illumina are significant competitors. The supply chain for 10x Genomics involves in-house manufacturing for highly specialized consumables subject to strict quality control, while relying on precision component sourcing for its hardware platforms, distributed through a direct sales force in the Americas and Europe, and channel partners in the Asia-Pacific region.
Market Share and Competitive Position
10x Genomics is the undisputed pioneer and reigning market leader in single-cell biology, maintaining a dominant market share estimated between 34% and 45% of the global single-cell analysis market. The company has essentially defined the standard for single-cell RNA sequencing over the last decade, supported by a massive installed base of over 7,000 instruments worldwide. This includes more than 5,800 Chromium systems, over 800 Visium systems, and more than 400 Xenium instruments deployed in elite laboratories globally. This ubiquity has resulted in an enormous moat built on academic mindshare, with tens of thousands of peer-reviewed publications utilizing 10x Genomics platforms. In the rapidly expanding spatial transcriptomics market, which accounts for nearly 80% of the spatial omics sector, the company has aggressively captured market share through the successful commercialization of Xenium. Following NanoString's bankruptcy and subsequent absorption by Bruker, 10x Genomics effectively capitalized on the market vacuum, consolidating its position as the premium provider of spatial transcriptomics hardware.
Competitive Advantages
The structural competitive advantage of 10x Genomics rests upon three pillars: an expansive intellectual property portfolio, a fully integrated end-to-end workflow, and formidable switching costs. The company holds over 1,200 granted patents and pending applications that cover foundational microfluidic architectures, proprietary chemistries, and crucial software algorithms. Management has proven highly aggressive in weaponizing this intellectual property to defend its market position, utilizing litigation to effectively neutralize competitors and impose high barriers to entry. Secondly, the seamless integration of its hardware, consumables, and analytical software creates a frictionless user experience. Researchers value data reproducibility and standardized workflows above all else, and the 10x Genomics ecosystem guarantees that a sample processed in Boston will yield directly comparable data to one processed in Tokyo. This reliability breeds high switching costs. Once a laboratory builds its bioinformatics pipelines, standard operating procedures, and multi-year longitudinal studies around the 10x Genomics architecture, the frictional cost and risk of migrating to a competing platform become prohibitively high, effectively locking in future consumable revenue streams.
Industry Dynamics: Opportunities and Threats
The life sciences tools industry is currently navigating a complex duality of secular tailwinds and severe macroeconomic headwinds. The primary opportunity lies in the rapid adoption of spatial biology and the growing use of single-cell data in artificial intelligence-driven drug discovery. Pharmaceutical companies are demanding massive, high-resolution cellular datasets to train predictive virtual cell models, an area where spatial transcriptomics provides unprecedented value by mapping gene expression within intact tissue architecture. Conversely, the immediate threat to the industry is a severely constrained capital expenditure environment. Academic funding fluctuations and a broad tightening of biopharmaceutical research budgets have drastically suppressed instrument purchases. This dynamic was starkly visible in the company's recent financial results, where total instrument revenue declined 36% in the fourth quarter of 2025 and fell a further 24% in the first quarter of 2026. While the high-margin consumables business has continued to deliver double-digit growth, masking some of the hardware weakness, the structural decline in instrument placements threatens to eventually choke off the pipeline for future consumable utilization if the capital equipment cycle does not normalize.
Pipeline and Future Growth Drivers
To reignite growth and command the next frontier of biological research, 10x Genomics is heavily betting on its newly announced Atera platform, which debuted in April 2026. Atera is engineered to completely redefine spatial biology by eliminating the historical tradeoffs between scale, sensitivity, and gene plexity. The platform enables whole-transcriptome in situ spatial analysis of up to 800 samples per year with single-cell sensitivity, profiling over 18,000 genes simultaneously across fresh-frozen and formal-fixed paraffin-embedded tissues. Scheduled to begin commercial shipments in the second half of 2026, Atera is positioned as a transformative growth engine that could spark a massive upgrade cycle among existing spatial researchers while capturing significant new translational research budgets. On the single-cell front, the company has successfully driven reaction volume growth by introducing lower-cost, highly flexible consumables such as the FLEX and FLEX Apex kits. These specialized products lower the economic barrier to running large-scale single-cell experiments, stimulating utilization rates on the existing Chromium installed base and ensuring consumable revenue expansion even in a stagnant hardware environment.
Emerging Disruptors and New Entrants
The most severe structural threat to 10x Genomics emerges not from superior hardware, but from the complete elimination of hardware. A new wave of competitors has commercialized instrument-free single-cell analysis techniques utilizing split-pool combinatorial barcoding and chip-free droplet emulsions. Parse Biosciences and Fluent BioSciences have spearheaded this disruption, offering highly scalable, cost-effective single-cell sequencing kits that require zero upfront capital equipment investment. This directly undermines the 10x Genomics Chromium instrument franchise. The credibility of this threat was permanently validated by major industry consolidation. In July 2024, the sequencing titan Illumina acquired Fluent BioSciences to integrate its instrument-free kits into the broader sequencing ecosystem. Subsequently, in November 2025, diagnostic giant Qiagen acquired Parse Biosciences for $225 million, immediately providing Parse with a massive global distribution network and deep institutional resources. With Qiagen projecting Parse to generate $40 million in its first year of integration, it is evident that instrument-free workflows are gaining rapid market traction, exerting structural downward pressure on the pricing power and hardware placement strategy of the legacy single-cell market leader.
Management Track Record
Under the leadership of Chief Executive Officer and Co-Founder Serge Saxonov, management has demonstrated a clinical pragmatism in navigating recent industry turbulence. When faced with deteriorating capital expenditure environments and rising instrument-free competition, management decisively pivoted away from a growth-at-all-costs mentality toward disciplined operational efficiency. Across 2024 and 2025, the company executed an 8% reduction in its global workforce and drastically curtailed operating expenses, which fell 15% year-over-year in the first quarter of 2026. Management also took the necessary but painful step of lowering consumable prices across the board to stimulate laboratory utilization and defend market share against cheaper, instrument-free upstarts. This strategy appears to be succeeding, as evidenced by double-digit reaction volume growth and improving gross margins that reached 70% in early 2026. Furthermore, management has successfully narrowed the operating loss from nearly $195 million in 2024 to $61 million in 2025, while maintaining an exceptionally strong balance sheet boasting $540 million in cash and marketable securities. The ruthless prosecution of intellectual property rights against NanoString further underscores a management team that is aggressively defensive of its foundational technology moat.
The Scorecard
10x Genomics occupies a highly enviable but increasingly contested position at the apex of the life sciences tools hierarchy. The company possesses an entrenched, high-margin consumables business backed by thousands of deployed instruments and a fierce intellectual property moat. The upcoming launch of the Atera platform promises to solidify its dominance in the rapidly growing spatial transcriptomics market, offering unprecedented whole-transcriptome analytical scale that currently lacks a direct technological peer. Management has proven highly adept at right-sizing the cost structure to preserve cash and drive towards operational profitability despite a brutal capital expenditure environment in the biopharmaceutical sector.
However, the structural erosion of the single-cell hardware franchise cannot be ignored. The rapid commercial validation of instrument-free technologies by deep-pocketed acquirers like Qiagen and Illumina presents a formidable, deflationary threat to the core Chromium business model. While 10x Genomics is successfully mitigating this by reducing consumable prices to drive volume, the days of relying on continuous, high-margin hardware placements to fuel the top line appear to be over. The investment thesis hinges entirely on whether the explosive growth in spatial biology via Atera and Xenium can outpace the inevitable commoditization and pricing pressures encroaching upon the legacy single-cell sequencing market.